Mean values at baseline and post-treatment (24 months) (number of letters on ETDRS chart)
| Variable | Ranibizumab (n=268) mean (SD) | Bevacizumab (n=249) mean (SD) |
|---|---|---|
| BCVA at baseline | 62.9 (14.6) | 62.0 (15.3) |
| BCVA at 24 months | 67.8 (17.0) | 66.1 (18.4) |
| Change from baseline | 4.9 (15.0) | 4.1 (13.5) |
BCVA, Best Corrected Visual Acuity.